This post has been archived and contains information that may be out of date.
The Department of Health & Human Services (HHS) has issued a proposed rule to rescind a Trump-era final rule requiring federally qualified health centers to fully pass along discounts they received from the 340B drug discount program for insulin and EpiPens to low-income or uninsured patients.
HHS seeks to overturn the rule due to administrative costs and burdens that implementation would cause for providers. Comments are due to HHS by 2 p.m. (PT) on July 16.